Is Epclusa a drug specifically designed to treat hepatitis C?

Epclusa is a broad-spectrum oral antiviral drug that is currently one of the first-line recommended options for the treatment of hepatitis C (HCV). It consists of two active ingredients: Sofosbuvir and Velpatasvir. The combination can effectively inhibit the replication of hepatitis C virus in the body. Genesate is designed to work against all six genotypes of hepatitis C virus and is the world's first approved pan-genotypic hepatitis C treatment.

The advent of Jisandai has greatly simplified the treatment process of hepatitis C. Before Jisandai, the treatment of hepatitis C often required different drug regimens based on the virus genotype, but Jisandai is suitable for all genotypes without the need for genotyping testing. The treatment cycle is usually 12 weeks, and the cure rate can reach more than 95%. This breakthrough in efficacy has made Jisandai the first choice for the radical treatment of hepatitis C in many countries and regions around the world.

In addition to its proven efficacy, Jisandai is also relatively well tolerated. Most patients experience mild side effects during use. Common discomforts include mild headache, fatigue, nausea, etc., and generally do not require interruption of treatment. For patients who have received treatment but have relapsed, or patients with a history of liver cirrhosis, doctors can also combine other drugs on the basis of Jisanda for intensive treatment based on specific circumstances.
To sum up, Jisandai is indeed a drug specially used to treat hepatitis C, and it has multiple advantages such as broad spectrum, simplified treatment plan, significant efficacy and low side effects. For hepatitis C patients who hope to achieve viral clearance through short-term oral medication, GISANDA provides a safe, effective and convenient treatment option.
Reference: https://www.epclusa.com/